InvestorsHub Logo
Followers 72
Posts 4827
Boards Moderated 0
Alias Born 01/24/2004

Re: freethemice post# 62569

Saturday, 03/26/2011 10:32:02 AM

Saturday, March 26, 2011 10:32:02 AM

Post# of 345554
FTM, when the 10-yr, $3bb Texas Cancer Project called CPRIT was formed back in 2009, I was very excited to see renowned scientist and Nobel Laureate Dr. Alfred Gilman named CSO, “to spearhead CPRIT's research division by leading the research grant process” (4-23-09 Forbes), since Dr. Gilman had publically commented years earlier about Dr. Phil Thorpe’s VTA work at UTSW in this manner:

JAN. 1998: ‘SOUTHWESTERN MEDICINE’ [UTSW], “CANCER KILLER” - BY SUSAN STEEVES
”The whole idea is predicated on an extraordinarily logical concept," said Dr. Alfred Gilman. The Nobel laureate and holder of the Raymond Willie & Ellen Willie Distinguished Chair in Molecular Neuropharmacology chairs the Dept. of Pharmacology at UT-SW. "The logic of Phil's [Philip Thorpe’s] theory is overwhelming and compelling. There are all sorts of problems associated with attacking malignant cells, such as their becoming resistant to treatments because they're growing and moving and doing all sorts of things that allow them to get away from you. The vascular endothelium isn't doing that; if you can target it successfully, you wipe out relatively small areas, and the blood will clot and kill off enormous numbers of tumor cells because you are cutting off their blood supply."

Not only that, but Dr. John D. Minna was named Chair of the CPRIT “Specific Areas of Research Need” Sub-Committee. In that same 1998 UTSW article, Dr. Minna said this about Dr. Thorpe’s work:

"I think Dr. Thorpe's technology, if it works, eventually could apply to maybe 90% of all cancers and certainly to 80% or 90% of the cancers that kill people," said Dr. John Minna, director of the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and the W.A. "Tex" and Deborah Moncrief Jr. Center for Cancer Genetics. "We don't know how early in a tumor's history its blood supply develops," said Minna, who also holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology. "For example in breast cancer and lung cancer, we know there are many different steps to give you genetic changes before you get a cancer. Then the cancer has to grow, and it's probably when it's a tenth of an inch or so in diameter that it would need the blood supply." By getting the clotting factor into one blood vessel, hundreds or thousands of tumor cells will die because they are starved. Other treatments require that a drug permeate every cancerous cell. "It's like a fire hose," said Minna, who also holds the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. "If you clamp off even one part of the hose, then no water will get through. I think there is the potential of having a huge amplification effect." Minna agrees. "Surgical resection plus Phil's drug or maybe chemotherapy or radiotherapy plus this may be the answer," he said. "In the solid tumors, what you have is a big ball of tumor cells; if you destroy its blood vessels, 95% of the cells are destroyed. But the very rim of cells around the surface, which get nutrients just by diffusion from the outside layers, would be handled more easily with the other therapies." . . . "I'm very excited about it," Minna said. "Of all the things that come through the pipeline, this is one of the most interesting things I've seen in my career. As I told Phil, it is my goal to be standing next to him at the bedside when we give the first dose of this to the first patient here at UT Southwestern. That will be an exciting time."
1998: http://www.swmed.edu/home_pages/publish/magazine/cancer/killer.html (link now dead)

Thus, back in June 2009, I thought that, with UTSW Drs. Gilman & Minna playing such prominent roles in CPRIT, with their clear knowledge of and complimentary public comments about Dr. Thorpe’s VTA work at UTSW, that eventually Dr. Thorpe would receive a CPRIT award to accelerate his lipid-targeting studies.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39031403
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42141457
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42147463

Well, it finally happened – announced 3-25-2011 by UTSW:
• CPRIT Awards $4,569,454 to Drs. Elizabeth Ward Ober, Ralph Mason, and Philip Thorpe to develop a new class of therapeutics to treat cancers involving the brain and nervous systems, breast, liver, interhepatic bile duct, lung, bronchs and prostate.
==> http://www.utsouthwestern.edu/utsw/cda/dept353744/files/633331.html

BTW, co-recipient Dr. Ralph Mason had collab’d with Dr. Phil Thorpe on Imaging apps for Anti-PS on many times in the past – see examples below.

= = = = = = = = = = = = = = = = =
3-25-11: CPRIT awards $36.7 million to UT-SW Investigators for Cancer Studies
UT Southwestern Medical Center
http://www.utsouthwestern.edu/utsw/cda/dept353744/files/633331.html
DALLAS, March 25, 2011: The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded more than $36.7 million in new grants to investigators at UTSW-MC to support cancer-related projects and to recruit pre-eminent cancer investigators. CPRIT was established in 2007 after Texas voters approved a constitutional amendment that authorized the state to fund cancer research & prevention programs. These awards, made after a rigorous peer-review process, resulted in UTSW receiving the most funding of any individual Texas institution in CPRIT’s latest round of grants. . . Funding for UTSW announced March 24 included more than $30 million to support projects involving 20 pre-eminent researchers. Among these are new imaging technology and techniques for identifying and tracking cancers; repairing damaged DNA strands; developing new drugs and drug-delivery systems; and establishing a Texas Cancer Cell Repository for storing cancer cells and tumors for future study. The awards also include $6 million to recruit pre-eminent researchers. “CPRIT funds are providing a powerful engine to attract the best and brightest minds to UTSW and to Texas,” said Dr. Daniel K. Podolsky, president of UTSW. “These awards will accelerate dramatically the impact of UT Southwestern research on cancer care and illustrate the importance of teams of physicians and investigators working together to defeat cancer.” Dr. James Willson, director of the Harold C. Simmons Comprehensive Cancer Center at UTSW, said, “The grant awards range from investigating the molecular mechanisms of cancer to developing novel therapies and ways to detect cancers. The funded projects highlight the forefront of translating basic science and laboratory findings into practical treatments & technologies.”
The breakdown of grants involving investigators at UTSW is: . . .
$4,569,454 to Drs. Elizabeth Ward Ober, Ralph Mason, and Philip Thorpe to develop a new class of
therapeutics to treat cancers involving the brain and nervous systems, breast, liver, interhepatic bile duct, lung, bronchs and prostate.
. . .
CPRIT AWARDEES ($30mm total to 20 UTSW researchers), including…
Dr. Ralph Mason, professor of radiology and director of the UTSW Cancer Imaging Center http://www.utsouthwestern.edu/findfac/research/0,2357,14638,00.html
Dr. Elizabeth Ward Ober, professor of immunology in the Cancer Immunobiology Center http://www8.utsouthwestern.edu/findfac/research/0,2357,17730,00.html
Dr. Philip Thorpe, professor of pharmacology in the Harold C. Simmons Comprehensive Cancer Center http://www.utsouthwestern.edu/findfac/research/0,2357,17308,00.html
Visit http://www.utsouthwestern.org/cancercenter to learn more about clinical services at UTSW for cancers.

= = = = = = = = = = = = = = = = = = =
3-3-08: P.Thorpe/R.Mason C.C.R. (AACR) article on Arsenic-labeled Bavi for Imaging Tumors: http://tinyurl.com/32jbfl
…3-5-08 Chemistry World followup article on CCR Bavi+Arsenic/IMAGING: http://tinyurl.com/4m4lbse

TWO DOD GRANTS TO P.THORPE/R.MASON (UTSW) FOR BAVI/AC PRE-CLINICAL STUDIES:
4-25-06 3rd DOD Grant W81XWH-06-1-0475: $460k, R.Mason, Bavi+Rad vs. Breast Cancer http://tinyurl.com/v9hye
Dr. Ralph Mason: "Since bavituximab's unique target is expressed on blood vessels in tumors but not in normal tissues, it may have both safety & efficacy advantages compared to other antibodies. We are eager to assess the utility of a bavituximab radioimmunoconjugate for the identification and treatment of metastatic breast disease."
Dr. Mason’s 6-2008 Bavi+Rad poster at DOD ‘Era of Hope’ Meeting (1-pg PDF): http://tinyurl.com/5e9r37
Dr. Mason’s 8-2006 poster at SMI-2006, “Optical Imaging of Exposed PS” (1-pg PDF): http://tinyurl.com/ys2afj
...Dr. Ralph Mason's 2-2006 Lecture Video w/6 mins. on Bavi: http://tinyurl.com/yqxngq
1-18-06 2nd DOD Grant W81XWH-06-1-0149: $585k, Mason, Bavi+Chemo vs. Prostate Cancer http://tinyurl.com/y683vn
Dr. Ralph Mason: "This new prostate cancer grant, which brings together the expertise of several disciplines at UT-SW, will employ advanced techniques such as MRI tumor oximetry to measure dynamic changes in the tumors. We expect that the findings of these studies will be directly applicable to the design of Bavituximab clin. trials for prostate cancer."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News